Follicular Lymphoma, Grade 3
4 clinical trials · Condition
◉ Watch Follicular Lymphoma, Grade 3
| Record | Firm | Date |
|---|---|---|
| Clinical Study of XNW5004 Tablets in the Treatment of Relapsed and Refractory Follicular Lymphoma (NCT07545603) | Evopoint Biosciences Inc. | 2026-02-14 |
| SynKIR-310 for Relapsed/Refractory B-NHL (NCT06544265) | Verismo Therapeutics | 2024-11-01 |
| Mosunetuzumab Consolidation Therapy After autoSCT in r/r Aggressive B Cell Lymphoma (NCT05412290) | Washington University School of Medicine | 2022-12-22 |
| Safety Study of SGN-CD70A in Cancer Patients (NCT02216890) | Seagen Inc. | 2014-08-01 |
Track Follicular Lymphoma, Grade 3 automatically
Every clearance here is in the API, with alerts when new ones post.